Revenue from operations remained flat at Rs 1,054.85 crore during the quarter under review as compared with Rs 1,054.80 crore in the year-ago period, Abbott India said in a regulatory filing.

The extended lockdown on account of COVID-19 has led to a slowdown in demand in some therapeutic areas and resulted in lower sales, it added.

The company continues to closely monitor the situation and will take appropriate measures in an attempt to mitigate any adverse impact, it said.

Visit news.dtnext.in to explore our interactive epaper!